2,8-dimethyl-5-(2-methyl-quinolin-6-yl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole | 1332450-18-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2,8-dimethyl-5-(2-methyl-quinolin-6-yl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole
• 英文别名: 2,8-dimethyl-5-(2-methylquinolin-6-yl)-3,4-dihydro-1H-pyrido[4,3-b]indole
• CAS: 1332450-18-6
• 化学式: C₂₃H₂₃N₃
• 分子量: 341.456
• InChiKey: YQXYNIMSTVDBQO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  26
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  21.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  6-溴-2-甲基喹啉 、 2,8-二甲基-2,3,4,5-四氢-1H-吡啶并[4,3-b]吲哚 在 potassium phosphate 、 copper(l) iodide 、 L-脯氨酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 2,8-dimethyl-5-(2-methyl-quinolin-6-yl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole
  参考文献：
  名称：

  [EN] COMPOUNDS AND METHODS OF TREATING DIABETES
  [FR] COMPOSÉS ET PROCÉDÉS DE TRAITEMENT DU DIABÈTE

  摘要：

  氢化吡啶并[4,3-b]吲哚，吡啶[3,4-b]吲哚和氮杂七环[4,5-b]吲哚已被描述。这些化合物可能与肾上腺素受体α2A结合并起拮抗作用。这些化合物也可能与肾上腺素受体α2B结合并起拮抗作用；或者这些化合物不是肾上腺素受体α2β的拮抗剂，这些化合物与第二种降低或预计会降低个体血压的药物一同给予。这些化合物可能在治疗中发挥作用，例如，调节血糖水平，增加胰岛素分泌并治疗疾病或病情，这些疾病或病情对胰岛素产生增加有反应或预计会有反应。特别描述了使用这些化合物治疗2型糖尿病。

  公开号：

  WO2012112962A1

文献信息

• [EN] PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]INDOLE DERIVATIVES AND METHODS OF USE<br/>[FR] DÉRIVÉS DE PYRIDO[4,3-B]INDOLE ET DE PYRIDO[3,4-B]INDOLE ET PROCÉDÉS D'UTILISATION
  申请人：MEDIVATION TECHNOLOGIES INC

  公开号：WO2011103430A1

  公开（公告）日：2011-08-25

  This disclosure is directed to tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本公开涉及四环吡啶并[4,3-b]吲哚和吡啶[3,4-b]吲哚。还提供了包含这些化合物的药物组合物，以及使用这些化合物进行各种治疗应用的方法，包括治疗认知障碍、精神病性障碍、神经递质介导的障碍和/或神经元障碍。
• COMPOUNDS AND METHODS OF TREATING DIABETES
  申请人：Protter Andrew Asher

  公开号：US20140155384A1

  公开（公告）日：2014-06-05

  Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor a 2A . The compounds may also bind to and are an antagonist of the adrenergic receptor α 2B ; or the compounds are not antagonists of the adrenergic receptor α2β and the compounds are administered in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual. The compounds may find use in therapy, e.g., to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. Use of the compounds to treat type 2 diabetes is particularly described.

  描述了氢化吡啶并[4,3-b]吲哚、吡啶[3,4-b]吲哚和氮杂七环[4,5-b]吲哚。这些化合物可以结合并拮抗肾上腺素受体a2A。这些化合物也可以结合并拮抗肾上腺素受体α2B；或这些化合物不是肾上腺素受体α2β的拮抗剂，并且这些化合物与第二种预计可以降低血压的药物一起使用于个体中。这些化合物可以用于治疗，例如，调节血糖水平，增加胰岛素分泌和治疗疾病或病况，这些疾病或病况对胰岛素产生增加反应。特别描述了使用这些化合物治疗2型糖尿病。
• COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION
  申请人：Protter Andrew Asher

  公开号：US20140296209A1

  公开（公告）日：2014-10-02

  Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor α 2B antagonists. The compounds may also bind to and antagonize adrenergic receptor α 1B —The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.

  本文描述了氢化吡啶[4,3-b]吲哚、吡啶[3,4-b]吲哚和氮杂七元[4,5-b]吲哚。这些化合物可以结合并拮抗肾上腺素受体α2B。这些化合物还可以结合并拮抗肾上腺素受体α1B。这些化合物可以用于治疗，例如：（i）降低血压和/或（ii）促进肾脏血流和/或（iii）减少或抑制钠重吸收。这些化合物也可以用于治疗预计对降低血压有响应的疾病或病况。本文特别描述了使用这些化合物治疗心血管和肾脏疾病的情况。
• PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE
  申请人：Chakravarty Sarvajit

  公开号：US20130190293A1

  公开（公告）日：2013-07-25

  This disclosure is directed to tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本文披露了四环吡啶并[4,3-b]吲哚和吡啶并[3,4-b]吲哚。该化合物的药物组合物也被提供，以及使用该化合物在各种治疗应用中的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。
• PYRIDO [4,3-B]INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE
  申请人：Medivation Technologies, Inc.

  公开号：US20160030446A1

  公开（公告）日：2016-02-04

  This disclosure is directed to tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本公开涉及四环吡啶[4,3-b]吲哚和吡啶[3,4-b]吲哚。还提供了包含该化合物的制药组合物，以及使用该化合物治疗多种治疗应用的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。